Journal of Internal Medicine Concepts & Practice >

2025 , Vol. 20 >Issue 04: 334 - 339

DOI: https://doi.org/10.16138/j.1673-6087.2025.04.14

Review

Advances in understanding the association between hyperuricemia and cardiovascular diseases

  • JIN Zhengyi ,
  • LIU Qilong ,
  • HU Jiaqi ,
  • XU Xia ,
  • GAO Jie
Expand
  • Department of Rheumatology and Immunology, the First Affiliated Hospital of Naval Medical University, Shanghai 200433, China

Received date: 2024-10-18

  Online published: 2025-10-27

Fold

Abstract

Hyperuricemia is a disease caused by abnormal purine metabolism. The prevalence of hyperuricemia is increasing annually in China. Elevated uric acid levels not only lead to gout attacks but are also associated with the occurrence and development of cardiovascular diseases. Research indicates that hyperuricemia can facilitate the onset and progression of cardiovascular diseases through promoting inflammation, causing endothelial dysfunction, and over activating the renin-angiotensin-aldosterone system. This review discusses the association between hyperuricemia and various cardiovascular diseases, including coronary atherosclerosis, atrial fibrillation, hypertension, and heart failure.

Key words： Hyperuricemia; Cardiovascular disease; Coronary atherosclerotic heart disease; Atrial fibrillation; Heart failure; Hypertension

Cite this article

JIN Zhengyi , LIU Qilong , HU Jiaqi , XU Xia , GAO Jie . Advances in understanding the association between hyperuricemia and cardiovascular diseases[J]. Journal of Internal Medicine Concepts & Practice, 2025 , 20(04) : 334 -339 . DOI: 10.16138/j.1673-6087.2025.04.14

References

[1] Li Z, Hoshino Y, Tran L, et al. Phylogenetic articulation of uric acid evolution in mammals and how it informs a therapeutic uricase[J]. Mol Biol Evol, 2021, 39(1):msab312.
[2] 方海琴, 姜萍, 王永俊, 等. 成人高尿酸血症与痛风食养指南(2024年版)[J]. 卫生研究, 2024, 53(3):352-356.
  Fang HQ, Jiang P, Wang YJ, et al. Dietary guidelines for adults with hyperuricemia and gout (2024 edition)[J]. J Hyg Res, 2024, 53(3):352-356.
[3] Gherghina ME, Peride I, Tiglis M, et al. Uric acid and oxidative stress-relationship with cardiovascular, metabolic, and renal impairment[J]. Int J Mol Sci, 2022, 23(6):3188.
[4] 朱慈燕, 孙扬, 韩辉. 代谢综合征患者血尿酸水平与骨密度关系的探讨[J]. 心血管康复医学杂志, 2023, 32(6):664-667.
  Zhu CY, Sun Y, Han H. Relationship between serum uric acid level and bone density in patients with metabolic syndrome[J]. Chin J Cardiovasc Rehabil Med, 2023, 32(6):664-667.
[5] 赵芳, 杨蓉, 苏玉霞, 等. 不同诊断标准下的代谢综合征与无症状心血管损害的相关性研究[J]. 同济大学学报(医学版), 2024, 45(2):189-196.
  Zhao F, Yang R, Su YX, et al. Incidence of asymptomatic cardiovascular impairments in patients with metabolic syndrome defined by different criteria[J]. J Tongji University (Med Sci), 2024, 45(2):189-196.
[6] 中国高血压防治指南修订委员会, 中国高血压联盟, 中国医疗保健国际交流促进会高血压病学分会, 等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志(中英文), 2024, 32(7):603-700.
  The Revision Committee of the Chinese Guidelines for the Prevention and Treatment of Hypertension, Chinese Hypertension League, Hypertension Division of the Chinese Medical Care and International Exchange Promotion Association, et al. Chinese guidelines for the prevention and treatment of hypertension (2024 revision edition)[J]. Chin J Hypertens, 2024, 32(7):603-700.
[7] Borghi C, Agnoletti D, Cicero A, et al. Uric acid and hypertension: A review of evidence and future perspectives for the management of cardiovascular risk[J]. Hypertension, 2022, 79(9):1927-1936.
[8] Cipolletta E, Tata LJ, Nakafero G, et al. Association between gout flare and subsequent cardiovascular events among patients with gout[J]. JAMA, 2022, 328(5):440-450.
[9] Yu W, Cheng JD. Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective[J]. Front Pharmacol, 2020, 11:582680.
[10] 吴小雯, 朱晓琳, 杨亚丽, 等. 无症状高尿酸血症对血管内皮功能的损害机制的研究进展[J]. 中国医药导报, 2023, 20(36):46-49.
  Wu XW, Zhu XL, Yang YL, et al. Research progress on the mechanism of damage of asymptomatic hyperuricemia to vascular endothelial function[J]. China Med Herald, 2023, 20(36):46-49.
[11] Park JH, Jin YM, Hwang S, et al. Uric acid attenuates nitric oxide production by decreasing the interaction between endothelial nitric oxide synthase and calmodulin in human umbilical vein endothelial cells: a mechanism for uric acid-induced cardiovascular disease development[J]. Nitric Oxide, 2013, 32:36-42.
[12] Du L, Zong Y, Li H, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy[J]. Signal Transduct Target Ther, 2024, 9(1):212.
[13] Zuo T, Liu X, Jiang L, et al. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies[J]. BMC Cardiovasc Disord, 2016, 16(1):207.
[14] 高明喜, 沈蕾, 施根灵, 等. 不同尿酸水平老年冠心病患者血管内超声检查结果比较研究[J]. 中华老年医学杂志, 2021, 40(3):297-300.
  Gao MX, Shen L, Shi GL, et al. A comparative study of intravascular ultrasound findings in elderly coronary heart disease patients with different uric acid levels[J]. Chin J Geriatr, 2021, 40(3):297-300.
[15] Zhang C, Jiang L, Xu L, et al. Implications of hyperuricemia in severe coronary artery disease[J]. Am J Cardiol, 2019, 123(4):558-564.
[16] 舒婷, 潘洁丽, 黄利, 等. 60岁以上不同血清尿酸水平的冠心病人群血管内超声显像特征分析[J]. 南京医科大学学报(自然科学版), 2019, 39(7):1048-1051.
  Shu T, Pan JL, Huang L, et al. Analysis of intravascular ultrasound imaging characteristics of coronary heart disease patients aged 60 years and older with different serum uric acid levels[J]. J Nanjing Med University (Nat Sci), 2019, 39(7):1048-1051.
[17] Wang K, Shi X, Zhu Z, et al. Mendelian randomization analysis of 37 clinical factors and coronary artery disease in East Asian and European populations[J]. Genome Med, 2022, 14(1):63.
[18] Sathvik M, Kalva E, Suma G. A study on acute myocardial infarction and its prognostic predictors[J]. Cureus, 2023, 15(2):e34775.
[19] Maloberti A, Giannattasio C, Bombelli M, et al. Hyperuricemia and risk of cardiovascular outcomes: the experience of the URRAH (Uric Acid Right for Heart Health) Project[J]. High Blood Press Cardiovasc Prev, 2020, 27(2):121-128.
[20] 陈强, 陈应忠, 崔彩艳, 等. 血尿酸水平与急性心肌梗死患者远期预后的关系研究[J]. 中国全科医学, 2022, 25(5):561-567.
  Chen Q, Chen YZ, Cui CY, et al. Serum uric acid and long-term prognosis in patients with acute myocardial infarction[J]. Chin Gen Pract, 2022, 25(5):561-567.
[21] 中华医学会老年医学分会心血管学组, 中国老年保健医学研究会老年心血管病分会. 老年心房颤动诊治中国专家共识(2024)[J]. 中华心律失常学杂志, 2024, 28(2):103-124.
  Cardiovascular Group, Geriatric Society of Chinese Medical Association Cardiovascular Branch, Chinese Society of Geriatric Health Medicine. Chinese expert consensus on the diagnosis and treatment of atrial fibrillation in the elderly (2024)[J]. Chin J Card Arrhythm, 2024, 28(2):103-124.
[22] 赵少华, 蔡军. 不同类型心房颤动患者血清尿酸、心型脂肪酸结合蛋白水平及其相关性[J]. 中国实用医刊, 2021, 48(7):13-16.
  Zhao SH, Cai J. Levels and correlation of uric acid, heart type fatty acid binding protein in patients with different types of atrial fibrillation[J]. Chin J Pract Med, 2021, 48(7):13-16.
[23] Wang X, Hou Y, Wang X, et al. Relationship between serum uric acid levels and different types of atrial fibrillation: an updated meta-analysis[J]. Nutr Metab Cardiovasc Dis, 2021, 31(10):2756-2765.
[24] Zhang J, Zheng R, Li H, et al. Serum uric acid and incident atrial fibrillation: a systematic review and dose-response meta-analysis[J]. Clin Exp Pharmacol Physiol, 2020, 47(11):1774-1782.
[25] Chen Y, Xia Y, Han X, et al. Association between serum uric acid and atrial fibrillation: a cross-sectional community-based study in China[J]. BMJ Open, 2017, 7(12):e019037.
[26] Taufiq F, Li P, Miake J, et al. Hyperuricemia as a risk factor for atrial fibrillation due to soluble and crystalized uric acid[J]. Circ Rep, 2019, 1(11):469-473.
[27] Zhang X, Hu M, Wang X, et al. New perspective on the risk markers for left atrial thrombosis in patients with atrial fibrillation[J]. Eur J Prev Cardiol, 2021, 28(6):641-647.
[28] Celik M, Yalcinkaya E, Yuksel UC, et al. Increased serum uric acid levels are correlated with decreased left atrial appendage peak flow velocity in patients with atrial fibrillation[J]. Med Princ Pract, 2015, 24(3):263-268.
[29] 北京高血压防治协会, 中国老年学和老年医学学会, 北京市社区卫生协会, 等. 成人高血压合并2型糖尿病和血脂异常基层防治中国专家共识(2024年版)[J]. 中国全科医学, 2024, 27(28):3453-3475.
  Beijing Hypertension Association, China Association of Gerontology and Geriatrics, Beijing Community Health Service Association, et al. Chinese expert consensus on grassroots prevention and treatment of hypertension combined with type 2 diabetes mellitus and dyslipidemia in adults 2024[J]. Chin Gen Pract, 2024, 27(28):3453-3475.
[30] Kawasoe S, Kubozono T, Ojima S, et al. J-shaped curve for the association between serum uric acid levels and the prevalence of blood pressure abnormalities[J]. Hypertens Res, 2021, 44(9):1186-1193.
[31] 钱莹, 马晓波, 高琛妮, 等. 慢性肾脏病患者高尿酸血症与高血压的关联分析[J]. 诊断学理论与实践, 2023, 22(2):160-165.
  Qian Y, Ma XB, Gao CN, et al. Association between hyperuricemia and hypertension in chronic kidney disease[J]. J Diagn Concept Pract, 2023, 22(2):160-165.
[32] 李祥科, 李盛世, 张小林, 等. 基于社区人群的血清尿酸水平与高血压发病率的6年随访研究[J]. 心脑血管病防治, 2021, 21(5):422-425.
  Li XK, Li SS, Zhang XL, et al. A six years observational cohort study of association between serum uric acid levels and the incidence of hypertension in community populations[J]. Prev Treat Cardio-Cerebral-Vascular Dis, 2021, 21(5):422-425.
[33] Lee JH. Prevalence of hyperuricemia and its association with metabolic syndrome and cardiometabolic risk factors in Korean children and adolescents: analysis based on the 2016-2017 Korea National Health and Nutrition Examination Survey[J]. Korean J Pediatr, 2019, 62(8):317-323.
[34] Reis LN, Reuter CP, Pollo RJ, et al. High urate concentration is associated with elevated blood pressure in schoolchildren[J]. J Pediatr Endocrinol Metab, 2018, 31(11):1207-1212.
[35] 樊彩妮, 赵海鹰, 王浩, 等. 大学生人群血清尿酸与高血压的相关性[J]. 中华高血压杂志, 2022, 30(2):173-177.
  Fan CN, Zhao HY, Wang H, et al. The correlation between serum uric acid and hypertension in college students[J]. Chin J Hypertens, 2022, 30(2):173-177.
[36] 任晓蕾, 詹轶秋, 张春燕, 等. 药源性高尿酸血症临床分析及风险管理[J]. 药物流行病学杂志, 2023, 32(9):969-974.
  Ren XL, Zhan YQ, Zhang CY, et al. Clinical analysis and risk management of drug-induced hyperuricemia[J]. Chin J Pharmacoepidemiol, 2023, 32(9):969-974.
[37] Muiesan ML, Salvetti M, Virdis A, et al. Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study[J]. J Hypertens, 2021, 39(1):62-69.
[38] Han Y, Cao Y, Han X, et al. Hyperuricemia and gout increased the risk of long-term mortality in patients with heart failure: insights from the National Health and Nutrition Examination Survey[J]. J Transl Med, 2023, 21(1):463.
[39] Miao L, Guo M, Pan D, et al. Serum uric acid and risk of chronic heart failure: a systematic review and meta-analysis[J]. Front Med (Lausanne), 2021, 8:785327.
[40] Deis T, Rossing K, Ersb?ll M K, et al. Uric acid in advanced heart failure: relation to central haemodynamics and outcome[J]. Open Heart, 2022, 9(2):e002092.
[41] Fu K, Cheng C, Su C, et al. Gender differences in the relationship between serum uric acid and the long-term prognosis in heart failure: a nationwide study[J]. Cardiovasc Diabetol, 2024, 23(1):131.
[42] White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout[J]. N Engl J Med, 2018, 378(13):1200-1210.
[43] Hashimoto H, Takeuchi M, Kawakami K. Association between urate-lowering therapy and cardiovascular events in patients with asymptomatic hyperuricemia[J]. Clin Rheumatol, 2023, 42(11):3075-3082.
[44] Konishi M, Kojima S, Uchiyama K, et al. Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease[J]. Int J Cardiol, 2022, 349:127-133.
[45] Deng H, Zhang BL, Tong JD, et al. Febuxostat use and risks of cardiovascular disease events, cardiac death, and all-cause mortality: metaanalysis of randomized controlled trials[J]. J Rheumatol, 2021, 48(7):1082-1089.
[46] Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial[J]. The Lancet, 2020, 396(10264):1745-1757.
[47] Johnson RJ, Choi HK, Yeo AE, et al. Pegloticase treatment significantly decreases blood pressure in patients with chronic gout[J]. Hypertension, 2019, 74(1):95-101.
[48] Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial[J]. Am J Kidney Dis, 2018, 72(6):798-810.
[49] Doehner W, Jankowska EA, Springer J, et al. Uric acid and xanthine oxidase in heart failure - emerging data and therapeutic implications[J]. Int J Cardiol, 2016, 213:15-19.
[50] Li Q, Wu C, Kuang W, et al. Correlation analysis of low-level serum uric acid and cardiovascular events in patients on peritoneal dialysis[J]. Int Urol Nephrol, 2021, 53(11):2399-2408.
[51] 吴秋彤, 茹晋丽, 李旭旭. 低血清尿酸对心脑血管疾病患者不良结局影响的研究进展[J]. 中华内分泌代谢杂志, 2022, 38(3):253-255.
  Wu QT, Ru JL, Li XX. The adverse effects of low serum uric acid on patients with cardiovascular and cerebrovascular diseases[J]. Chin J Endocrinol Metab, 2022, 38(3):253-255.
[52] Bi M, Feng A, Liu Y, Tian S. U-shaped association of serum uric acid with cardiovascular disease risk scores and the modifying role of sex among Chinese adults[J]. Nutr Metab Cardiovasc Dis, 2023, 33(5):1066-1076.
Options
Outlines

/

〈 〉